Press Releases from Leaders in Pharmaceutical Business Intelligence (LPBI): FIVE new e-Book in our BioMed e-Series are NOW available for Kindle on Amazon.com
Editor-in-Chief, BioMED e-Series: Aviva Lev-Ari, PhD, RN
2016 WE ARE ON AMAZON.COM
http://www.amazon.com/dp/B00DINFFYC
http://www.amazon.com/dp/B018Q5MCN8
http://www.amazon.com/dp/B018PNHJ84
http://www.amazon.com/dp/B018DHBUO6
http://www.amazon.com/dp/B013RVYR2K
http://www.amazon.com/dp/B012BB0ZF0
http://www.amazon.com/dp/B019UM909A
http://www.amazon.com/dp/B019VH97LU
Leaders in Pharmaceutical Business Intelligence (LPBI) would like to announce the First volume of their BioMedical E-Book Series B: Series B: Frontiers in Genomics Research, Volume One is available for Amazon.com Kindle
Newton, MA — (ReleaseWire) — 01/19/2016 — Leaders in Pharmaceutical Business Intelligence would like to announce the First volume of their BioMedical E-Book Series B: Series B: Frontiers in Genomics Research
Volume I: Genomics Orientations for Individualized Medicine which is now available on Amazon Kindle at
http://www.amazon.com/dp/B018DHBUO6
For more information visit:
Leaders in Pharmaceutical Business Intelligence (LPBI) Would Like to Announce Volume III of Their BioMedical E-Book Series E: Patient-Centered Medicine
LPBI Announces New e-Book available on Amazon! Volume Three: Milestones in Physiology & Discoveries in Medicine and Genomics
Newton, MA — (ReleaseWire) — 01/14/2016 — Leaders in Pharmaceutical Business Intelligence would like to announce Volume III of their BioMedical E-Book Series E: Patient-Centered Medicine
Volume Three: Milestones in Physiology & Discoveries in Medicine and Genomics which is now available on Amazon Kindle at
http://www.amazon.com/dp/B019VH97LU
For more information visit:
Leaders in Pharmaceutical Business Intelligence (LPBI) Would Like to Announce the Second Volume of Their BioMedical E-Book Series A: E-Books on Cardiovascular Diseases
New e-Book Available on Amazon.com! Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation
Newton, MA — (ReleaseWire) — 01/15/2016 — Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation which is now available on Amazon Kindle at
http://www.amazon.com/dp/B018Q5MCN8
For more information visit:
Leaders in Pharmaceutical Business Intelligence (LPBI) Would Like to Announce the Third Volume of Their BioMedical E-Book Series A: E-Books on Cardiovascular Diseases
LPBI Announces New e-Book available now on Amazon.com! Volume Three: Etiologies of Cardiovascular Diseases – Epigenetics, Genetics and Genomics
Newton, MA — (ReleaseWire) — 01/14/2016 — Leaders in Pharmaceutical Business Intelligence would like to announce the Third volume of their BioMedical E-Book Series A: e-Books on Cardiovascular Diseases.
Volume Three: Etiologies of Cardiovascular Diseases – Epigenetics, Genetics and Genomics which is now available on Amazon Kindle at
http://www.amazon.com/dp/B018PNHJ84
For more information visit:
Leaders in Pharmaceutical Business Intelligence (LPBI) announces Amazon e-Book for Kindle Volume Four: Therapeutic Promise: Cardiovascular Diseases, Regenerative & Translational Medicine
LPBI Announces New e-Book available now on Amazon.com! Volume Four: Therapeutic Promise: Cardiovascular Diseases, Regenerative & Translational Medicine
Newton, MA — (ReleaseWire) — 01/15/2016 — Volume Four: Therapeutic Promise: Cardiovascular Diseases, Regenerative & Translational Medicine which is now available on Amazon Kindle at
http://www.amazon.com/dp/B019UM909A
For more information visit:
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.